Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib

Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Akiko, Ohkubo, Hirotsugu, Fukumitsu, Kensuke, Fukuda, Satoshi, Kanemitsu, Yoshihiro, Takemura, Masaya, Maeno, Ken, Ito, Yutaka, Oguri, Tetsuya, Niimi, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522408/
https://www.ncbi.nlm.nih.gov/pubmed/30568147
http://dx.doi.org/10.2169/internalmedicine.1890-18
_version_ 1783419109313085440
author Nakano, Akiko
Ohkubo, Hirotsugu
Fukumitsu, Kensuke
Fukuda, Satoshi
Kanemitsu, Yoshihiro
Takemura, Masaya
Maeno, Ken
Ito, Yutaka
Oguri, Tetsuya
Niimi, Akio
author_facet Nakano, Akiko
Ohkubo, Hirotsugu
Fukumitsu, Kensuke
Fukuda, Satoshi
Kanemitsu, Yoshihiro
Takemura, Masaya
Maeno, Ken
Ito, Yutaka
Oguri, Tetsuya
Niimi, Akio
author_sort Nakano, Akiko
collection PubMed
description Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment with nintedanib, high-resolution computed tomography findings revealed reduced areas of ground-glass opacity and consolidation; 13 months after treatment, the FVC showed improvement from 3.07 to 3.43 L, and the serum Krebs von den Lungen (KL)-6 concentration showed a decline to normal levels. We herein report a patient with IPF who was considered a super responder to nintedanib.
format Online
Article
Text
id pubmed-6522408
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-65224082019-05-20 Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib Nakano, Akiko Ohkubo, Hirotsugu Fukumitsu, Kensuke Fukuda, Satoshi Kanemitsu, Yoshihiro Takemura, Masaya Maeno, Ken Ito, Yutaka Oguri, Tetsuya Niimi, Akio Intern Med Case Report Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment with nintedanib, high-resolution computed tomography findings revealed reduced areas of ground-glass opacity and consolidation; 13 months after treatment, the FVC showed improvement from 3.07 to 3.43 L, and the serum Krebs von den Lungen (KL)-6 concentration showed a decline to normal levels. We herein report a patient with IPF who was considered a super responder to nintedanib. The Japanese Society of Internal Medicine 2018-12-18 2019-04-15 /pmc/articles/PMC6522408/ /pubmed/30568147 http://dx.doi.org/10.2169/internalmedicine.1890-18 Text en Copyright © 2019 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Nakano, Akiko
Ohkubo, Hirotsugu
Fukumitsu, Kensuke
Fukuda, Satoshi
Kanemitsu, Yoshihiro
Takemura, Masaya
Maeno, Ken
Ito, Yutaka
Oguri, Tetsuya
Niimi, Akio
Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title_full Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title_fullStr Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title_full_unstemmed Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title_short Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib
title_sort remarkable improvement in a patient with idiopathic pulmonary fibrosis after treatment with nintedanib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522408/
https://www.ncbi.nlm.nih.gov/pubmed/30568147
http://dx.doi.org/10.2169/internalmedicine.1890-18
work_keys_str_mv AT nakanoakiko remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT ohkubohirotsugu remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT fukumitsukensuke remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT fukudasatoshi remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT kanemitsuyoshihiro remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT takemuramasaya remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT maenoken remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT itoyutaka remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT oguritetsuya remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib
AT niimiakio remarkableimprovementinapatientwithidiopathicpulmonaryfibrosisaftertreatmentwithnintedanib

Ejemplares similares